Assessment of the efficacy and safety of fampridine
<p><strong>Objective:</strong> Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis.</p> <p><strong>Method:</strong> A descriptive retrospective study of all patients who initiated treatment w...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/10615.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p><strong>Objective:</strong> Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis.</p>
<p><strong>Method:</strong> A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015. Efficacy was assessed through the 25-foot walk test and the 12-item walking scale for multiple sclerosis. It was reviewed whether patients had suffered any of the most frequent adverse effects described in the pivotal clinical trial.</p>
<p><strong>Results:</strong> Six patients were included, with a 66.7% response rate. At 3-6 months, the mean change in walking speed (compared to baseline) was 39.32% and there was a mean improvement of 15 points in the walking scale. Only one patient presented adverse effects.</p>
<p><strong>Conclusions:</strong> The results obtained are encouraging, particularly when fampridine is the only drug currently approved to control such a disabling symptom as instability while walking. </p> |
|---|---|
| ISSN: | 1130-6343 2171-8695 |